Decreased caudate N-acetyl-l-aspartic acid in pediatric obsessive-compulsive disorder and the effects of behavior therapy

Psychiatry Research - Neuroimaging

Volumn 202, Issue 1, 2012, Pages 53-59

  Whiteside, Stephen P H ^a   Abramowitz, Jonathan S ^b   Port, John D ^a  

^a MAYO CLINIC   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

Author keywords

Behavior therapy; Exposure and response prevention; Magnetic resonance spectroscopy; N acetyl l aspartate; Obsessive compulsive disorder; Pediatric

Indexed keywords

GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

ADOLESCENT; ANTERIOR CINGULATE; ARTICLE; BEHAVIOR THERAPY; CASE CONTROL STUDY; CAUDATE NUCLEUS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIFESPAN; MALE; NEUROCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE BLIND PROCEDURE;

ADOLESCENT; ASPARTIC ACID; BEHAVIOR THERAPY; CAUDATE NUCLEUS; CHILD; FEMALE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OBSESSIVE-COMPULSIVE DISORDER; TREATMENT OUTCOME;

EID: 84862566327     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2011.11.010     Document Type: Article

References (43)

1. Apostolova I., Block S., Buchert R., Osen B., Conradi M., Tabrizian S., Gensichen S., Schroder-Hartwig K., Fricke S., Rufer M., Weiss A., Hand I., Clausen M., Obrocki J. Effects of behavioral therapy or pharmacotherapy on brain glucose metabolism in subjects with obsessive-compulsive disorder as assessed by brain FDG PET. Psychiatry Research: Neuroimaging 2010, 184:105-116.
2. Bartha R., Stein M.B., Williamson P.C., Drost D.J., Neufeld R.W., Carr T.J., Canaran G., Densmore M., Anderson G., Siddiqui A.R. A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. The American Journal of Psychiatry 1998, 155:1584-1591.
3. Baxter L.R., Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., Alazraki A., Selin C.E., Ferng H., Munford P., Phelps M.E. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. The American Journal of Psychiatry 1992, 49(9):1560-1563. (Sep 1992).
4. Benazon N.R., Moore G.J., Rosenberg D.R. Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:1279-1285.
5. Carey P.D., Warwick J., Niehaus D.J.H., van der Linden G., van Heerden B.B., Harvey B.H., Seedat S., Stein D.J. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 2004, 4:30.
6. Carlsson M.L. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2001, 25:5-26.
7. Ebert D., Speck O., Konig A., Berger M., Hennig J., Hohagen F. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Research: Neuroimaging 1997, 74:173-176.
8. Fitzgerald K.D., Moore G.J., Paulson L.A., Stewart C.M., Rosenberg D.R. Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder.[comment]. Biological Psychiatry 2000, 47:174-182.
9. Frances A., Docherty J.P., Kahn D.A. Treatment of obsessive-compulsive disorder. The Journal of Clinical Psychiatry 1997, 58:5-72.
10. Gehring W.J., Himle J., Nisenson L.G. Action-monitoring dysfunction in obsessive-compulsive disorder. Psychological Science 2000, 11:1-6. (Jan 2000).
11. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale: II. Validity. Archives of General Psychiatry 1989, 46:1012-1016.
12. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleishmann R.L., Hill C.L., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Archives of General Psychiatry 1989, 46:1006-1011.
13. Huyser C., Veltman D.J., Wolters L.H., de Haan E., Boer F. Functional magnetic resonance imaging during planning before and after cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49:1238-1248.
14. Huyser C., Veltman D.J., Wolters L.H., de Haan E., Boer F. Developmental aspects of error and high-conflict-related brain activity in pediatric obsessive-compulsive disorder: a fMRI study with a Flanker task before and after CBT. Journal of Child Psychology and Psychiatry 2011, 52:1251-1260.
15. Kitamura H., Shioiri T., Kimura T., Ohkubo M., Nakada T., Someya T. Parietal white matter abnormalities in obsessive-compulsive disorder: a magnetic resonance spectroscopy study at 3-Tesla. Acta Psychiatrica Scandinavica 2006, 114:101-108.
16. March J.S., Mulle K. OCD in Children and Adolescents: A Cognitive-Behavioral Treatment Manual 1998, Guilford Press, New York.
17. Muris P., Schmidt H., Merckelbach H. Correlations among two self-report questionnaires for measuring DSM-defined anxiety disorder symptoms in children: The Screen for Child Anxiety Related Emotional Disorders and the Spence Children's Anxiety Scale. Personality and Individual Differences 2000, 28:333-346.
18. Muris P., Merckelbach H., Ollendick T., King N., Bogie N. Three traditional and three new childhood anxiety questionnaires: their reliability and validity in a normal adolescent sample. Behaviour Research and Therapy 2002, 40:753-772.
19. Nakao T., Nakagawa A., Yoshiura T., Nakatani E., Nabeyama M., Yoshizato C., Kudoh A., Tada K., Yoshioka K., Kawamoto M., Togao O., Kanba S. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biological Psychiatry 2005, 57:901-910.
20. Nauta M.H., Scholing A., Rapee R.M., Abbott M., Spence S.H., Waters A. A parent-report measure of children's anxiety: psychometric properties and comparison with child-report in a clinic and normal sample. Behaviour Research and Therapy 2004, 42:813-839.
21. Pfund Z., Chugani D.C., Juhasz C., Muzik O., Chugani H.T., Wilds I.B., Seraji-Bozorgzad N., Moore G.J. Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and 1H magnetic resonance spectroscopy in patients with epilepsy. Journal of Cerebral Blood Flow and Metabolism 2000, 20:871-878.
22. POTS Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial. JAMA: The Journal of the American Medical Association 2004, 292:1969-1976.
23. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 1993, 30:672-679.
24. Rauch S.L. Neuroimaging research and the neurobiology of obsessive-compulsive disorder: where do we go from here?[comment]. Biological Psychiatry 2000, 47:168-170.
25. Rooney M.T., Fristad M.A., Weller E.B., Weller R.A. Adminstration Manual for the ChIPS 1999, American Psychiatric Press, Inc., Washington, DC.
26. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive- compulsive disorder patients taking paroxetine. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39:1096-1103.
27. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee S.P., Bhandari R., Rose M., Ivey J., Boyd C., Moore G.J. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43:1146-1153.
28. Rotge J.-Y., Guehl D., Dilharreguy B., Cuny E., Tignol J., Bioulac B., Allard M., Burbaud P., Aouizerate B. Provocation of obsessive-compulsive symptoms: A quantitative voxel-based meta-analysis of functional neuroimaging studies. Journal of Psychiatry & Neuroscience 2008, 33:405-412.
29. Rotge J.-Y., Guehl D., Dilharreguy B., Tignol J., Bioulac B., Allard M., Burbaud P., Aouizerate B. Meta-analysis of brain volume changes in obsessive-compulsive disorder. Biological Psychiatry 2009, 65:75-83.
30. Saxena S., Bota R.G., Brody A.L. Brain-behavior relationships in obsessive-compulsive disorder. Seminars in Clinical Neuropsychiatry 2001, 6:82-101.
31. Saxena S., Gorbis E., O'Neill J., Baker S.K., Mandelkern M.A., Maidment K.M., Chang S., Salamon N., Brody A.L., Schwartz J.M., London E.D. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Molecular Psychiatry 2009, 14:197-205.
32. Scahill L., Riddle M.A., McSwiggin-Hardin M., Ort S.I., King R.A., Goodman W., Cicchetti D., Leckman J.F. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36:844-852.
33. Sled J.G., Zijdenbos A.P., Evans A.C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Transactions on Medical Imaging 1998, 17:87-97.
34. Spence S.H. A measure of anxiety symptoms among children. Behaviour Research and Therapy 1998, 36:545-566.
35. Storch E.A., Murphy T.K., Geffken G.R., Soto O., Sajid M., Allen P., Roberti J.W., Killiany E.M., Goodman W.K. Psychometric evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale. Psychiatry Research 2004, 129:91-98.
36. Sumitani S., Harada M., Kubo H., Ohmor T. Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients. Psychiatry Research: Neuroimaging 2007, 154:85-92.
37. Van Veen V., Carter C.S. The anterior cingulate as a conflict monitor: fMRI and ERP studies. Physiology & Behavior 2002, 77:477-482.
38. Vogt B.A., Hof P.R., Vogt L.J. Cingulate gyrus. The Human Nervous System (2nd ed.) 2004, 915-949. Academic Press, San Diego. G. Paxinos, J.K. Mai, JKM (Eds.).
39. Whiteside S.P., Port J.D., Abramowitz J.S. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 2004, 132:69-79.
40. Whiteside S.P., Port J.D., Deacon B.J., Abramowitz J.S. A Magnetic Resonance Spectroscopy Investigation of Obsessive-Compulsive Disorder and Anxiety. Psychiatry Research: Neuroimaging 2006, 146:137-147.
41. Whiteside S.P.H., Abramowitz J.S., Port J.D. The effect of behavior therapy on caudate N-acetyl-l-aspartic acid in adults with obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 2012, 201(1):10-16.
42. Yamanishi T., Nakaaki S., Omori I.M., Hashimoto N., Shinagawa Y., Hongo J., Horikoshi M., Tohyama J., Akechi T., Soma T., Iidaka T., Furukawa T.A. Changes after behavior therapy among responsive and nonresponsive patients with obsessive-compulsive disorder. Psychiatry Research 2009, 172:242-250.
43. Yucel M., Wood S.J., Wellard R.M., Harrison B.J., Fornito A., Pujol J., Velakoulis D., Pantelis C. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. The Australian and New Zealand Journal of Psychiatry 2008, 42:467-477.